Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele
- 12 January 2014
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 31 (2) , 1-7
Abstract
Somatic inactivation of the remaining allele is a characteristic feature of cancers arising in BRCA1 and BRCA2 mutation carriers, which determines their unprecedented sensitivity to some DNA-damaging agents. Data on tumor-specific status of the involved gene in novel varieties of hereditary breast cancer (BC) remain incomplete. We analyzed 32 tumors obtained from 30 patients with non-BRCA1/2 BC-associated germ-line mutations: 25 women were single mutation carriers (7 BLM, 15 CHEK2 and 3 NBN/NBS1) and 5 were double mutation carriers (2 BLM/BRCA1, 1 CHEK2/BLM, 1 CHEK2/BRCA1 and 1 NBN/BLM). Losses of heterozygosity affecting the wild-type allele were detected in none of the tumors from BLM mutation carriers, 3/18 (17 %) CHEK2-associated BC and 1/4 (25 %) NBN/NBS1-driven tumors. The remaining 28 BC were subjected to the sequence analysis of entire coding region of the involved gene; no somatic mutations were identified. We conclude that the tumor-specific loss of the wild-type allele is not characteristic for BC arising in CHEK2, NBN/NBS1 and BLM mutation carriers. Rarity of “second-hit” inactivation of the involved gene in CHEK2-, NBN/NBS1- and BLM-associated BC demonstrates their substantial biological difference from BRCA1/2-driven cancers and makes them poorly suitable for the clinical trials with cisplatin and PARP inhibitors.Keywords
This publication has 23 references indexed in Scilit:
- CHEK2 1100delC mutation is frequent among Russian breast cancer patientsBreast Cancer Research and Treatment, 2006
- Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individualsBritish Journal of Cancer, 2005
- Haploinsufficiency for tumour suppressor genes: when you don't need to go all the wayBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2004
- The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.2003
- Germline 657del5 mutation in the NBS1 gene in breast cancer patientsInternational Journal of Cancer, 2003
- CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumoursBritish Journal of Cancer, 2002
- Enhanced Tumor Formation in Mice Heterozygous for Blm MutationScience, 2002
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002
- Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds.1994
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971